Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Xenon Pharmaceuticals Inc. - Common Shares
(NQ:
XENE
)
44.84
-0.17 (-0.38%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 26, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Xenon Pharmaceuticals Inc. - Common Shares
< Previous
1
2
3
4
5
6
7
8
9
Next >
Biohaven Ltd. (BHVN): A High-Stakes Clinical Crossroad in Neuroscience and Immunology
December 26, 2025
As of December 26, 2025, Biohaven Ltd. (NYSE: BHVN) finds itself at a critical juncture. Once the darling of the biotech sector following a staggering $11.6 billion acquisition of its migraine...
Via
PredictStreet
Topics
Economy
Intellectual Property
Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares
↗
December 08, 2025
Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares
Via
The Motley Fool
Topics
Regulatory Compliance
Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025
December 05, 2025
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Earnings Scheduled For November 3, 2025
↗
November 03, 2025
Via
Benzinga
A Look Ahead: Xenon Pharmaceuticals's Earnings Forecast
↗
August 08, 2025
Via
Benzinga
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 04, 2025
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Up 44% Since IPO: Why a Major Fund Just Made a $45 Million Bet on This Digital Health Stock
↗
December 03, 2025
One fast-growing digital health stock just secured a notable new backer—right as its financial momentum hits a fresh gear.
Via
The Motley Fool
Topics
Initial Public Offering
Regulatory Compliance
Acadia Stock Up 59% in a Year — Is a $51 Million New Stake a Bet on a Bigger Rebound?
↗
December 03, 2025
One fund is quietly buying into ACADIA — just as the company posts one of its strongest quarters in years.
Via
The Motley Fool
Soleno Turns First Profit on $66 Million in Revenue — Is This Why One Investor Just Made an $87 Million Bet?
↗
December 03, 2025
Soleno just turned profitable for the first time—right as a major fund made its move.
Via
The Motley Fool
Topics
Regulatory Compliance
With a 150% Rally and Big 2026 Catalysts Ahead, Is Amylyx Stock Getting a Second Chance?
↗
December 03, 2025
One investor is making a bold bet on Amylyx just as its 2026 catalyst calendar starts to take shape.
Via
The Motley Fool
Topics
Regulatory Compliance
Scholar Rock Stock Is Still Down 40% From 2021 Highs — And One Investor Just Walked Away
↗
December 03, 2025
This investor just walked away as Scholar Rock heads into a pivotal 2026—here’s what that means for long-term shareholders.
Via
The Motley Fool
Topics
Regulatory Compliance
Terns Stock Surges 300% in One Year — What a New $43 Million Position Signals for Investors
↗
December 03, 2025
One fast-rising biotech just landed a heavyweight backer ahead of a pivotal presentation—here’s what investors should watch.
Via
The Motley Fool
Topics
Regulatory Compliance
Relay Therapeutics Stock Has Jumped 60% in a Year — And One Investor Just Bought Nearly 4 Million More Shares
↗
December 03, 2025
Relay’s comeback is gaining momentum—does this latest move signal rising conviction in its pipeline?
Via
The Motley Fool
Topics
Regulatory Compliance
Xenon Announces Investor Webinar Highlighting Azetukalner and Epilepsy Data from AES 2025
December 03, 2025
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon to Present New Azetukalner OLE Study Data in Epilepsy at AES 2025
November 25, 2025
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon to Present at Upcoming Investor Conferences
November 06, 2025
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
These stocks are moving in today's after hours session
↗
November 03, 2025
As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
Via
Chartmill
Xenon Reports Third Quarter 2025 Financial Results & Business Update
November 03, 2025
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Insights into Xenon Pharmaceuticals's Upcoming Earnings
↗
October 31, 2025
Via
Benzinga
Xenon to Report Q3 2025 Financial Results on November 3, 2025
October 27, 2025
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Announces Appointment of Tucker Kelly as Chief Financial Officer
October 16, 2025
Mr. Kelly is a proven strategic CFO with significant financial, operational and commercialization leadership experience
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 07, 2025
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Announces Upcoming Investor Webinar to Discuss Early-Stage Ion Channel Programs for the Potential Treatment of Pain
September 25, 2025
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Design Therapeutics Appoints Justin Gover to Board of Directors
September 10, 2025
From
Design Therapeutics, Inc.
Via
GlobeNewswire
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 29, 2025
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Reports Second Quarter 2025 Financial Results & Business Update
August 11, 2025
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon to Report Q2 2025 Financial Results on August 11, 2025
August 04, 2025
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Earnings Scheduled For August 11, 2025
↗
August 11, 2025
Via
Benzinga
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 01, 2025
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Biogen Shares Slip After $46M Research Charge Hits Quarterly Profit
↗
July 07, 2025
The company anticipates a research expense in Q2 associated with milestone and licensing payments, which will impact both GAAP and non-GAAP earnings per share.
Via
Stocktwits
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
